CORDIS
EU research results

CORDIS

English EN
Development of an immunotherapy for breast cancer based on dendritic cells by developing and comparing different types of tumor specific immunogens

Development of an immunotherapy for breast cancer based on dendritic cells by developing and comparing different types of tumor specific immunogens

Objective

This project aims for the development of an effective immunotherapy for breast cancer, based on dendrite cell vaccines. This includes the generation of dendrite cells, the production of breast cancer related immunises, the development and improvement of new strategies for enhanced antigen presentation the in vitro evaluation of immune response using patients T-cells and mouse models and the transfer of the most successful approach to GMP as well the design of a clinical trial. The project requires collaboration between medical oncologists and scientists with expertise in cancer immunology, dendrite cells therapy, biotechnology, basic molecular biology and glycobiology. Cancer vaccines based on dendrite cells are the focus of attention worldwide and the leading company in Europe; IDM is a participant in this project.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FORSCHUNGSZENTRUM JUELICH GMBH

Address

Leo-Brand-Strasse
52425 Juelich

Germany

Administrative Contact

Joachim TREUSCH (Professor)

Participants (7)

Sort alphabetically

Expand all

CANCER RESEARCH UK

United Kingdom

GOETEBORG UNIVERSITY

Sweden

IMMUNO DESIGNED MOLECULES SA

France

UNIVERSITY HOSPITAL MAASTRICHT

Netherlands

UNIVERSITY OF COPENHAGEN

Denmark

UNIVERSITY OF ZURICH

Switzerland

VRIJE UNIVERSITEIT AMSTERDAM - VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS

Netherlands

Project information

Grant agreement ID: QLK3-CT-2002-01980

  • Start date

    1 November 2002

  • End date

    31 October 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 657 552

  • EU contribution

    € 1 845 447

Coordinated by:

FORSCHUNGSZENTRUM JUELICH GMBH

Germany